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Purpose: Teduglutide, a glucagon-like peptide-2 analog, has demonstrated efficacy in reducing 
parenteral support (PS) among patients with short bowel syndrome with intestinal failure 
(SBS–IF). This study aims to identify a subpopulation of SBS–IF patients for whom teduglutide 
has an especially pronounced effect.
Patients and methods: Data were from a 24-week, Phase III trial (Study of Teduglutide 
Effectiveness in Parenteral Nutrition-Dependent SBS Subjects; NCT00798967) that randomized 
SBS–IF patients with PS dependency to receive teduglutide (n=43) or placebo (n=43). Two 
prediction models (1 for each arm) were developed for response, defined as 20% reduction in 
weekly PS at Weeks 20 and 24. Potential predictors included demographics, disease charac-
teristics, and concomitant medications. Patients were then ranked based on the effect score, an 
individualized predicted response rate difference with teduglutide versus placebo. A subpopu-
lation of patients with a pronounced benefit from teduglutide versus placebo was identified. 
Baseline characteristics and clinical outcomes were compared between patients included versus 
those not included in the subpopulation.
Results: Six predictors of response to teduglutide were selected: older age, volvulus as the 
cause of major intestinal resection, baseline PS volume .6 L per week, longer time since start 
of PS dependency, absence of ileocecal valve, and lower percentage of colon remaining. Higher 
percentage of colon remaining and volvulus were the selected predictors for response to placebo. 
A subpopulation of patients more likely to respond to teduglutide was identified as those with 
the top 60% effect scores. The difference in response rate between teduglutide and placebo 
was 62% in the subpopulation, which was substantially higher than the difference of 33% in 
the overall population. Mean PS day reduction was also significantly higher for teduglutide 
compared to placebo in the subpopulation.
Conclusion: Pretreatment characteristics as predictors of response to teduglutide versus placebo 
within 24 weeks were identifiable in the clinical trial population of SBS–IF patients.
Keywords: SBS, intestinal failure, teduglutide, subpopulation
Introduction
Short bowel syndrome (SBS) is a rare malabsorption disorder caused by massive 
resection of small intestine, congenital defect, or disease-associated loss of absorption.1 
It is a subcategory of intestinal failure (IF), which is defined as, “the reduction of gut 
function below the minimum necessary for the absorption of macronutrients and/or 
water and electrolytes, such that intravenous supplementation is required to maintain 
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health and/or growth” according to the 2016 European Society 
for Clinical Nutrition and Metabolism guidelines.2,3 The most 
common causes of SBS associated with IF (SBS–IF) in 
adults include Crohn’s disease, acute bowel infarction, radia-
tion strictures, and adhesive obstruction.4,5 The severity of 
SBS–IF is affected by factors such as the sites and extent of 
resection, the quality of the remnant intestinal mucosa, the 
ability of the patient to compensate orally for malabsorption, 
and, ultimately, the remnant absorptive capacity of remain-
ing bowels.6–8 Although the prevalence of SBS–IF in adults 
is not known, it has been estimated that ~10,000–20,000 
individuals in the USA and 4 individuals per million in the 
European population have SBS–IF.9–11
A variety of metabolic and physiologic complications are 
known to be associated with SBS–IF, such as nutrient defi-
ciencies, fluid and electrolyte disturbances, and diarrhea.12 
Because of functional losses of the resected small intestine, a 
substantial number of SBS patients require parenteral support 
(PS) for supplemental nutrients, fluids, and electrolytes, 
which is potentially associated with severe complications 
such as liver and kidney damage.10 Therefore, treatments 
improving the intestinal absorption of fluids and nutrients 
and reducing the frequency and volume of PS are emerging 
for patients with SBS–IF.
Somatropin, a human growth hormone, and glutamine, 
an α-amino acid, were approved by the US Food and Drug 
Administration (FDA) to treat SBS patients receiving 
nutritional support in 2003 and 2004, respectively.13,14 Despite 
the potential positive effect of human growth hormone with or 
without glutamine on energy absorption and weight gain, the 
benefit was short lived and did not continue after cessation of 
the treatment.15 Side effects were prominent. In 2012, tedu-
glutide, an analog of glucagon-like peptide-2, was approved 
by the FDA and European Medicines Agency (EMA) for the 
treatment of adult patients with SBS–IF receiving nutritional 
support. In 2016, the EMA approved teduglutide for the 
treatment of pediatric patients ($1 year) with SBS–IF. It was 
the third approved treatment by the FDA and the first by the 
EMA for this indication.16,17 Teduglutide has been shown to 
be efficacious in reducing the need for PS in 24 weeks and 
during 2 years of follow-up in clinical studies.18,19 Although 
almost all SBS–IF patients with PS dependency eventually 
responded to teduglutide in the clinical trial, the heterogeneity 
of treatment response across patient subpopulations was not 
evaluated. Identification of subpopulations with response to 
teduglutide can inform the optimization of treatment out-
comes and health care resource use. This post hoc study used 
pretreatment characteristics of the cohort that participated in 
the teduglutide registration trial to identify a subpopulation 
of SBS–IF patients for whom teduglutide has an especially 
pronounced effect during the 24 weeks of follow-up.
Materials and methods
study population
The present study was a post hoc analysis of the STEPS 
(Study of Teduglutide Effectiveness in Parenteral Nutrition-
Dependent SBS Subjects) trial (NCT00798967), a random-
ized, double-blind, placebo-controlled Phase III study 
conducted in 10 countries across Europe and North 
America.18 The trial included adults with a history of SBS–IF 
that resulted in PS dependency. A total of 86 patients were 
randomized in a 1:1 ratio to receive placebo or teduglutide 
0.05 mg/kg/day for 24 weeks. The primary endpoint of the 
STEPS trial was defined as a 20%–100% reduction in weekly 
PS (ie, parenteral nutrition and/or intravenous fluid volume) 
from baseline to Week 20, maintained at Week 24. The intent-
to-treat population from the STEPS trial was included in the 
current analysis. The trial was approved by local institutional 
review boards or medical ethics committees (Table S1). All 
participants provided written informed consent.
study measures
Baseline characteristics
Baseline characteristics including patient demographics 
(ie, age, sex), SBS characteristics (ie, cause of major intes-
tinal resection, presence of stoma, percentage of colon 
remaining, presence of distal and terminal ileum, presence of 
ileocecal valve), PS characteristics (ie, baseline PS volume 
at randomization, time since start of PS dependency), and 
concomitant narcotics use were collected for the analysis. 
Missing data in percentage of colon remaining were imputed 
based on whether a patient had colon in continuity. For 
patients without colon in continuity, missing data in percent-
age of colon remaining were imputed as 0; for patients with 
colon in continuity, missing data were imputed as the mean 
percentage of colon remaining.
Outcomes
This analysis identified subpopulations of patients that are 
more likely to achieve response when treated with teduglutide 
compared to placebo in the 24-week trial. Response was 
defined as the achievement of $20% reduction from baseline 
in weekly PS at Week 20, maintained at Week 24. Additional 
outcomes evaluated in the study included reduction in PS 
days and change in SBS quality of life (QoL) score. PS 
volume was recorded daily by patients in an electronic diary, 
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and reduction in PS days was calculated as the difference in 
number of days with PS between Week 24 and baseline.18 QoL 
in patients with SBS was evaluated using an SBS-specific 
patient-reported outcomes QoL instrument (ie, SBS-QoL).20 
Change in SBS-QoL score was calculated as the difference 
between Week 24 and baseline. The SBS-QoL score ranged 
from 0 to 170, representing “perfect” to “worst” QoL, and 
the minimal clinically important difference was defined as 
a positive change of score from baseline above the 2-fold 
measurement error of the SBS-QoL (ie, 18.4).21
analysis
Descriptions of baseline characteristics and 
outcomes in the overall population
Baseline characteristics and outcomes were summarized 
for the teduglutide and placebo arms. Means and SDs were 
reported for continuous variables and counts, and propor-
tions were reported for categorical variables. Comparisons 
between teduglutide and placebo arms were conducted using 
Wilcoxon rank-sum tests for continuous characteristics and 
chi-square or Fisher’s exact tests (if expected cell counts ,5) 
for categorical characteristics.
Prediction of responses to teduglutide and placebo
To identify patients with an especially pronounced 24-week 
treatment benefit from teduglutide versus placebo, we first 
ranked them based on predicted level of benefit from tedu-
glutide. The predicted level of benefit for each patient was 
estimated as the difference between his or her predicted 
response rates with teduglutide or placebo. These individual-
ized predictions of response rates were obtained from mul-
tivariable models fit to each arm. For the teduglutide arm, a 
prediction model for response was estimated using logistic 
regression. Ten baseline characteristics were considered, 
based on clinical input and data availability, as candidate 
predictors, including age, sex, cause of major intestinal 
resection, presence of stoma, percentage of colon remain-
ing, presence of distal/terminal ileum, presence of ileocecal 
valve, baseline PS volume at randomization, and time since 
start of PS dependency. To identify a parsimonious model, 
and to account for the limited sample size and avoid over-
fitting, a penalized regression approach was used to fit the 
model and to select a subset of important predictors from 
the list of candidates.22,23 The same approach was used to 
develop a separate prediction model for the placebo arm. 
The in-sample predictive performance and calibration of 
each prediction model was evaluated using c statistics and 
Hosmer–Lemeshow tests.24
Identification of a higher response subpopulation for 
teduglutide
After developing the aforementioned prediction models, 
an effect score, an individualized predicted response rate 
difference with teduglutide versus placebo based on the 
prediction models, was estimated for individual patients. 
Patients were then ranked according to this effect score. This 
ranking provides a basis for defining subpopulations that 
exhibit treatment effect heterogeneity. Highly ranked patients 
will show greater benefits for teduglutide in 24 weeks; lower-
ranked patients will show smaller benefits at that time point. 
Subpopulations can be defined by applying thresholds to 
the effect score (Figure S1). This approach has been used to 
identify subpopulations that benefit most from treatment in 
previous clinical trials.22,25–28
A systematic approach to evaluating these subpopulations 
borrows an idea from economics: the efficiency frontier or 
selection impact curve.29 For any subpopulation, we can ask 
2 questions: 1) what fraction of the total population falls 
into the subpopulation and 2) what response rate would we 
expect in the full population if teduglutide was used only in 
the subpopulation. At one extreme, the effect score threshold 
can be set to the highest observed value. The fraction of the 
population exceeding this threshold is 0%, and the estimated 
response rate in the full population with 0% receiving tedu-
glutide is equivalent to the response rate in the placebo arm 
of the STEPS trial. At the other extreme, the effect score 
threshold is set below the lowest observed value. The frac-
tion of the population exceeding this threshold is 100%, and 
the estimated response rate in the full population with 100% 
receiving teduglutide is equivalent to the response rate in 
the teduglutide arm of STEPS. Between these 2 extremes, 
a series of increasing effect score thresholds will describe a 
relationship between treating more patients with teduglutide, 
starting with those expected to benefit most and incrementally 
expanding to those expected to benefit least, and the overall 
response rate in the full population. The curve linking these 
scenarios and describing the relationship between the pro-
portions of patients treated and population response rate is 
an efficiency frontier, which represents the highest response 
rate that can be achieved for each level of teduglutide use 
based on the effect scores.
In the present study, patients were ranked by their 
individual effect scores from highest to lowest and were 
sequentially grouped as potential subpopulations by 10% 
increments, starting from the top 20% of patients with the 
highest individual effect score until all patients (100%) were 
included. The initial threshold of 20% was selected to ensure 
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that at least 10 patients were included in the subpopulation. 
Within each of these subpopulations, the observed response 
rates to teduglutide and placebo and the difference in these 
observed response rates were estimated. Response rate in 
the overall population was estimated using a hypothetical 
assignment rule where patients in the potential subpopula-
tions received teduglutide and the rest of the population 
received placebo. The efficiency frontier was then plotted 
as the convex hull of the size of the potential subpopula-
tions (horizontal axis) and the corresponding response rates 
in the overall population (vertical axis). Bootstrapping was 
applied to estimate the 95% CI for the efficiency frontier. 
Based on the efficiency frontier, a subpopulation of patients 
with a particularly pronounced response rate benefit from 
teduglutide versus placebo was identified. To characterize 
this subpopulation, baseline characteristics were summarized 
and compared between patients included versus not included 
in the subpopulation. Clinical outcomes, including response 
rate, reduction in PS days, and change in SBS-QoL, were 
also summarized and compared. Descriptive summaries were 
conducted using SAS 9.4 (SAS Institute, Inc., Cary, NC, 
USA). All other analyses were performed using R version 
3.3.2 (http://cran.r-project.org).
Results
Baseline characteristics and prespecified 
trial analysis outcomes
All patients in the trial (N=86) were included in the analysis; 
43 were randomized to teduglutide and 43 were randomized 
to placebo. Baseline characteristics were generally well bal-
anced between the teduglutide and placebo arms (Table 1), 
with the exception of presence of ileocecal valve, which was 
significantly less frequent in the teduglutide arm compared 
to the placebo arm (7.0% versus 23.3%, P=0.04). Mean age 
was comparable in the teduglutide (50.9 years) and placebo 
(49.7 years) arms, and the majority of the patients were 
white (teduglutide: 97.7%; placebo: 95.3%; P-value not 
significant). Proportions of men were 48.8% and 44.2% in 
the teduglutide and placebo arms, respectively. Mesenteric 
vascular disease was the most common cause of major intes-
tinal resection in this patient population; 83% of patients 
had a PS volume .6 L/week at randomization, with a mean 
duration of PS dependency of 6.4 years.
Overall, the response rate was significantly higher in 
patients treated with teduglutide compared to placebo based 
on data collected at Weeks 20 and 24 (teduglutide versus 
placebo: 62.8% versus 30.2%, P,0.01). The aforementioned 
Table 1 Baseline characteristics of sBs–iF patients in the sTePs trial
Characteristics Teduglutide 
(n=43)
Placebo 
(n=43)
P-value
Demographics
age (years), mean (sD) 50.9 (12.6) 49.7 (15.6) 0.82
Male, n (%) 21 (48.8) 19 (44.2) 0.67
White, n (%) 42 (97.7) 41 (95.3) 1.00
Baseline SBS characteristics
Cause of major intestinal resection, n (%)
Crohn’s disease 10 (23.3) 8 (18.6) 0.60
Vascular disease 13 (30.2) 16 (37.2) 0.49
injury 4 (9.3) 4 (9.3) 1.00
Volvulus 3 (7.0) 6 (14.0) 0.48
Cancer 1 (2.3) 2 (4.7) 1.00
Other 12 (27.9) 7 (16.3) 0.19
Presence of stoma, n (%) 21 (48.8) 17 (39.5) 0.39
Percentage of colon remaining, mean (sD) 33.9 (31.8) 40.9 (40.6) 0.39
Presence of distal/terminal ileum, n (%) 10 (23.3) 14 (32.6) 0.34
Presence of ileocecal valve, n (%) 3 (7.0) 10 (23.3) 0.04*
Baseline PS characteristics
Baseline Ps volume at randomization, n (%) 0.78
#6 l/week 8 (18.6) 7 (16.3)
.6 l/week 35 (81.4) 36 (83.7)
Time since start of Ps dependency (years), mean (sD) 6.8 (6.3) 5.9 (5.7) 0.76
Concomitant narcotics use, n (%) 15 (34.9) 12 (27.9) 0.49
Note: *P,0.05.
Abbreviations: Ps, parenteral support; sBs, short bowel syndrome; sBs–iF, sBs with intestinal failure; sTePs, study of Teduglutide effectiveness in Parenteral nutrition-
Dependent sBs subjects.
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results were obtained from the prespecified analysis of the 
STEPS trial.18
Prediction models for response
A total of 6 baseline characteristics, including age, cause of 
major intestinal resection, baseline PS volume, time since 
start of PS dependency, presence of ileocecal valve, and per-
centage of colon remaining, were selected as predictors for 
response to teduglutide (Table 2). Among the selected predic-
tors for response to teduglutide, older age (odds ratio 1.023), 
volvulus as the cause of major intestinal resection (odds 
ratio 3.765), baseline PS volume .6 L per week (odds ratio 
4.750), and longer time since start of PS dependency (odds 
ratio 1.010) were associated with higher odds of response to 
teduglutide; presence of ileocecal valve (odds ratio 0.550) 
and higher percentage of colon remaining (odds ratio 0.980) 
were associated with lower odds of response to teduglutide. 
Two characteristics, percentage of colon remaining and cause 
of major intestinal resection, were selected as predictors for 
response to placebo (Table 2). Specifically, higher percent-
age of colon remaining (odds ratio 1.003) and volvulus as 
the cause of major intestinal resection (odds ratio 1.238) 
were associated with higher odds of response to placebo. 
C statistics suggested good performance in both prediction 
models (teduglutide: 0.88; placebo: 0.74). The models were 
well calibrated (Hosmer–Lemeshow test P-values of 0.15 
and 0.26 for teduglutide and placebo, respectively).
a higher response subpopulation for 
teduglutide
Differences in response to teduglutide and placebo across 
the studied range of subpopulations are depicted in Figure 1. 
In the subpopulation of patients with the highest 20% of 
effect scores (ie, effect score $0.54), patients treated with 
teduglutide demonstrated a higher response rate compared 
to those treated with placebo by +80.0%. The difference in 
response rates between teduglutide and placebo decreased 
when more patients with lower effect scores were included in 
the subpopulation. When all patients were included (ie, 100% 
of the study sample), the difference in response rates between 
teduglutide and placebo was +32.6%, the same rate reported 
in the clinical trial.18 This treatment effect heterogeneity was 
attributable to both increased response rates to teduglutide 
and decreased response rates to placebo as the effect score 
increased (Figure 2).
The efficiency frontier, shown in Figure 3, describes the 
tradeoffs between the size of the subpopulation receiving 
teduglutide and the resulting response rate in the overall 
population. The observed probability of response in the 
overall population increased when more patients received 
teduglutide. However, the curve reaches a shoulder as the 
percentage of patients receiving teduglutide exceeds 60%, 
indicating that most of the teduglutide treatment benefit for 
overall response rate was achieved when ~60% of the patients 
received teduglutide. Therefore, a subpopulation of patients 
more likely to respond to teduglutide was identified as the 
patients with the top 60% effect scores.
Patients in this higher-response subpopulation (n=51) had 
a mean age of 52.0 years, balanced sex (51.0% male), and 
Crohn’s disease as the most common cause of major intes-
tinal resection (31.4%). The majority of these patients were 
without distal/terminal ileum or ileocecal valve (Table 3). 
Compared to the lower-response subpopulation (n=35), 
proportion with colon in continuity (35.3% versus 88.6%, 
Table 2 Prediction models for response to teduglutide and placebo
Predictors selected by regression models Teduglutide Placebo
Coefficient Odds 
ratio
Coefficient Odds 
ratio
intercept −1.263 −0.988
Percentage of colon remaining −0.020 0.980 0.003 1.003
Cause of major intestinal resection (volvulus versus other) 1.326 3.765 0.214 1.238
Presence of ileocecal valve (yes versus no) −0.598 0.550
age (years) 0.023 1.023
Baseline Ps volume at randomization (.6 l per week versus #6 l per week) 1.558 4.750
Time since start of Ps dependency (years) 0.010 1.010
Model performance
C statisticsa 0.88 0.74
P-value of hosmer–lemeshow testb 0.15 0.26
Notes: aa C statistic of 1 corresponds to perfect prediction; a C statistic of 0.5 corresponds to a prediction rule that does not perform any better than a random prediction. 
bThe Hosmer–Lemeshow test is a goodness-of-fit test. P,0.05 indicates a lack of fit.
Abbreviation: Ps, parenteral support.
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P,0.01) and percentage of colon remaining (18.5 versus 
65.0, P,0.01) were significantly lower in the higher-
response subpopulation.
Clinical outcomes were also evaluated within and 
between subpopulations (Table 4). Among patients in the 
higher-response subpopulation, patients treated with tedu-
glutide had significantly better response rate (87.5% versus 
25.9%, P,0.01) and significantly higher mean reduction in 
PS days (1.0 versus 0.4, P=0.01), compared to those treated 
with placebo. The difference in response rate between 
teduglutide and placebo was 61.6% in the higher response 
subpopulation, which was also substantially higher than the 
difference of 32.6% in the overall population. In contrast, 
all evaluated clinical outcomes (ie, response, reduction in PS 
days, and change in SBS-QoL) were comparable between 
teduglutide- and placebo-treated patients among the lower-
response subpopulation (ie, patients with lower 60% effect 
scores; Table 4).
Discussion
The present study evaluated the predictability of response 
to teduglutide and to use a model-based individual effect 
score to identify patients who are more likely to achieve a 
response to teduglutide in patients with SBS–IF at 24 weeks. 
Within the Phase III STEPS trial, we were able to accurately 
predict response among patients treated with teduglutide 
??? ?? ?? ??
?????????????????????????????????????????????????????????????????????????????
????
????
????
????
????
??
???
???
?????
?????
???
???
????
?
????????????
?????????????
?????? ?????? ????? ????? ????? ????? ????? ????? ?????
?? ?? ?? ?? ???
??
??
??
??
??
??
??
??
??
Figure 1 Difference in response between teduglutide and placebo in potential subpopulations.
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Figure 2 Response in potential subpopulations by treatment.
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and placebo based on patient characteristics measured at 
baseline. These predictive models were used to identify 
a subpopulation of patients who were especially likely to 
experience a response to teduglutide within 24 weeks. Within 
this subpopulation, the increase in the response rate with 
teduglutide versus placebo exceeded 60%, nearly double the 
effect size in the overall population. The subpopulation was 
identified without cherry-picking or data-dredging, and the 
??
??
??
??
??
??
??
??
?? ? ?? ?? ?? ?? ?? ?? ?? ?? ??
???????????????????????????
???????????????????????????????????????????????
???
????
????
???
?????
?
????
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?
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Figure 3 Efficiency frontier.
Table 3 Comparison of baseline characteristics in the higher- and lower-response subpopulations
Baseline characteristics Higher-response 
subpopulation 
(n=51)
Lower-response 
subpopulation 
(n=35)
P-value
Demographics
age (years), mean (sD) 52.0 (14.1) 47.8 (14.0) 0.27
Male, n (%) 26 (51.0) 14 (40.0) 0.32
White, n (%) 48 (94.1) 35 (100.0) 0.27
Disease characteristics
Cause of major intestinal resection, n (%)
Crohn’s disease 16 (31.4) 2 (5.7) ,0.01*
Vascular disease 10 (19.6) 19 (54.3) ,0.01*
injury 4 (7.8) 4 (11.4) 0.71
Volvulus 7 (13.7) 2 (5.7) 0.30
Cancer 3 (5.9) 0 (0.0) 0.27
Other 11 (21.6) 8 (22.9) 0.89
Colon in continuity, n (%) 18 (35.3) 31 (88.6) ,0.01*
Percentage of colon remaining, mean (sD) 18.5 (26.3) 65.0 (31.3) ,0.01*
estimated remaining small intestine length (cm), mean (sD) 87.0 (70.6) 61.6 (51.7) 0.07
estimated remaining small intestine length (cm), n (%) 0.11
,60 20 (42.6) 20 (60.6)
$60 27 (57.4) 13 (39.4)
Presence of distal/terminal ileum, n (%) 9 (17.6) 15 (42.9) 0.01*
Presence of ileocecal valve, n (%) 2 (3.9) 11 (31.4) ,0.01*
Presence of stoma, n (%) 33 (64.7) 5 (14.3) ,0.01*
Time since last small bowel resection (years), mean (sD) 6.6 (6.1) 8.2 (8.6) 0.88
Baseline PS characteristics
Baseline Ps volume at randomization, n (%) ,0.01*
#6 l/week 1 (2.0) 14 (40.0)
.6 l/week 50 (98.0) 21 (60.0)
Time since start of Ps dependency (years), mean (sD) 6.7 (5.8) 5.8 (6.3) 0.20
Concomitant narcotics use, n (%) 16 (31.4) 11 (31.4) 1.00
Note: *P,0.05.
Abbreviation: Ps, parenteral support.
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key subjective decision was the list of candidate predictors, 
which was specified before data analysis. It is worth noting 
that the present study investigated predictors of outcomes 
among SBS patients who were PS dependent for at least 
12 months following intestinal resection. The identified 
predictors may, therefore, differ from those for postsurgical 
outcomes among recently resected patients.
Diversity in response to treatment may occur because 
of patients’ individual disease characteristics, variations in 
genetic composition, and environmental factors.30,31 Specifi-
cally, individualized management for patients with SBS–IF 
should be considered given variations in diagnosis, remaining 
bowel length/function, and psychosocial characteristics.32 
Optimal treatment strategies can be informed by an under-
standing of how individual patients may respond differently 
to treatment. The UK National Institute for Health and Care 
Excellence has published a review on how subpopulations 
should be considered to maximize health gains for both 
clinical efficacy and cost-effectiveness.33 Guidelines like this 
have provided foundations for the development of algorithms 
and methods for subpopulation identification.
In rare diseases, there is often more heterogeneity 
among patients, which further complicates the understand-
ing of treatment benefit. It is important to consider different 
patient characteristics in support of individualized treat-
ment approaches. The US National Institutes of Health 
has developed a program called Therapeutics for Rare and 
Neglected Diseases, which may help to optimize the treat-
ment effects on rare diseases by identifying subgroups of 
patients who can benefit more from a potential drug.30 Using 
clinical trial data, the current study demonstrates substantial 
heterogeneity in response to treatment among patients with 
SBS–IF. Using appropriate methods, we are able to identify 
a higher-response subpopulation even with a limited sample 
size. Results from this study may help guide more efficient 
treatment and management of SBS–IF. The approach could 
also potentially be applied to other rare disease areas to 
identify the right population for the right treatment.
The present study has shown that identifying patient and 
disease characteristics associated with response to tedug-
lutide within 24 weeks is feasible among SBS–IF patients. 
Patients in the identified subpopulation were characterized 
by absence of distal/terminal ileum or ileocecal valve, a 
lower likelihood of having colon in continuity, and a lower 
percentage of colon remaining. These patient characteristics 
are well supported by the phenotypic feature of SBS–IF 
patients. Specifically, SBS–IF patients with a preserved 
terminal ileum and ileocecal valve and a substantial part of 
the colon are characterized by having more normal gastric 
emptying, gastric acid secretion, and a good structural and 
functional adaptation compared to patients with a jejunos-
tomy. This may not only relate to the fluid, electrolyte, and 
energy-salvaging effects of the preserved colon, but also to 
a preserved or even elevated endogenous hormone secretion 
and neuroendocrine feedback signaling from the distal to the 
proximal gastrointestinal tract. Therefore, the effect of and 
response to exogenous supplementation of the glucagon-like 
peptide-2 (GLP-2) analog teduglutide may be better in the 
patients with a jejunostomy who lack their endogenous post-
prandial GLP-2 secretion and are characterized phenotypi-
cally by accelerated gastric emptying, gastric hypersecretion, 
and poor adaptation following resection.
Based on the clinical efficacy reported in the STEPS-2 
trial (ie, the extension study of the STEPS trial), the majority 
of the patients that did not respond to teduglutide within 
24 weeks eventually responded during the extension phase. 
Therefore, this analysis does not lead to the identification 
of a specific etiology for response to teduglutide or patient 
selection criteria for teduglutide treatment among SBS–IF 
patients but aims instead at identifying characteristics linked 
to an earlier response to teduglutide within 24 weeks. Because 
the large majority of patients with SBS–IF eventually respond 
to teduglutide treatment, knowing whether they are likely to 
achieve an earlier response within 24 weeks may help set 
more accurate patient and physician expectations and encour-
age treatment persistence. For patients with characteristics of 
Table 4 Comparison of clinical outcomes between teduglutide and placebo in subpopulations
Clinical outcome Higher-response subpopulation Lower-response subpopulation
Teduglutide 
(n=24)
Placebo 
(n=27)
P-value Teduglutide 
(n=19)
Placebo 
(n=16)
P-value
Response rate, n (%) 21 (87.5) 7 (25.9) ,0.01* 6 (31.6) 6 (37.5) 0.71
Reduction in Ps days, mean (sD) 1.0 (1.2) 0.4 (0.9) 0.01* 0.8 (1.0) 0.7 (0.9) 0.51
Change in sBs-Qol, mean (sD) −12.2 (31.3) −8.5 (31.1) 0.57 −11.2 (20.5) −2.6 (30.2) 0.59
Note: *P,0.05.
Abbreviations: Ps, parenteral support; Qol, quality of life; sBs, short bowel syndrome.
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the lower-response subpopulation, knowing that a longer time 
to response is typical for their patient profile could prevent 
early treatment discontinuation and support waiting for long-
term treatment benefits. Thus, the clinical implications of this 
research are more focused on setting appropriate expectations 
and managing adherence to teduglutide than informing which 
patients should or should not be treated.
This study comes with some limitations. First, the data used 
in the study were from a clinical trial population comprising 
only patients that met specific inclusion and exclusion criteria. 
Therefore, the results may not be generalizable to other SBS–IF 
populations. Second, the candidate baseline characteristics for 
predicting response were limited in number because of the 
small sample size and were selected among the characteristics 
collected during the baseline period of the clinical trial. There 
may be important subpopulations defined by as-yet unknown 
or unmeasured biomarkers or clinical characteristics. Finally, 
the statistical power of the analysis and the robustness of the 
prediction models may be limited by small sample size.
In conclusion, teduglutide has demonstrated better 
response within 24 weeks compared to placebo in a random-
ized, double-blind, placebo-controlled Phase III clinical 
trial of an SBS–IF population. The present study was able 
to identify pretreatment characteristics as predictors of 
response to teduglutide versus placebo within 24 weeks and 
a higher-response subpopulation for this time period with a 
limited study sample. The analytical approach can potentially 
be applied to other disease areas to inform more efficient 
treatment and management of the disease. Research in per-
sonalized treatment selection will serve as an important step 
in improving patient care and optimizing treatment efficiency. 
The current analysis is considered exploratory, and further 
analysis to prospectively assess reproducibility of the results 
in a separate population is warranted.
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Figure S1 Illustration of subpopulation identification based on effect score.a
Notes: aPatients were ranked by their individual effect scores from highest to lowest and were sequentially grouped together as potential subpopulations by 10% increments, 
starting from the top 20% of patients with the highest individual effect score, until all patients (100%) were included.
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0109 University of Pennsylvania institutional Review Board
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0115 Cleveland Clinic institutional Review Board
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0201 Vanderbilt University Medical Center institutional Review Board
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0101 University health network Research ethics Board
0106 st Michael’s Research ethics Board
0202 hamilton health sciences Corporation Research ethics Board
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